Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Operating Leases — Right-of-Use (ROU) Assets by Year
Operating Leases — Right-of-Use (ROU) Assets ($M) ($M)
Merck Operating Leases — Right-of-Use (ROU) Assets: $1,507M in FY2025, up 10.0% from a year earlier.
Latest, FY2025
1,507
Period ended Dec 31, 2025
Change on a year earlier
+10.0%
1,370 in FY2024
History
7 years
Since FY2019
Sources
6
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-K Note 10 Leases.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Operating Leases — Right-of-Use (ROU) Assets ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,507 | +10.0% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 1,370 | -4.7% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 1,437 | +6.8% | Form 10-K (filed 2025-02-25) ↗ |
| FY2022 | Dec 31, 2022 | 1,346 | -15.1% | Form 10-K (filed 2024-02-26) ↗ |
| FY2021 | Dec 31, 2021 | 1,586 | -6.0% | Form 10-K (filed 2023-02-24) ↗ |
| FY2020 | Dec 31, 2020 | 1,688 | +57.3% | Form 10-K (filed 2022-02-25) ↗ |
| FY2019 | Dec 31, 2019 | 1,073 | – | Form 10-K (filed 2021-02-25) ↗ |
Breakdown
What makes up operating Leases — Right-of-Use (ROU) Assets
- Operating Lease Liabilities — Total ($M)1,195 · FY2025
- Operating Lease Liabilities — Current ($M)294 · FY2025
- Operating Lease Liabilities — Noncurrent ($M)901 · FY2025
- ROU Assets Obtained in Exchange for New Operating Lease Liabilities ($M)162 · FY2025
- Operating Lease Undiscounted Cash Flows — Year 1 ($M)335 · FY2025
- Operating Lease Undiscounted Cash Flows — Year 2 ($M)261 · FY2025
- Operating Lease Undiscounted Cash Flows — Year 3 ($M)204 · FY2025
- Operating Lease Undiscounted Cash Flows — Year 4 ($M)125 · FY2025
- Operating Lease Undiscounted Cash Flows — Year 5 ($M)103 · FY2025
- Operating Lease Undiscounted Cash Flows — Thereafter ($M)415 · FY2025
- Operating Lease Undiscounted Cash Flows — Total ($M)1,443 · FY2025
- Operating Leases — Less Imputed Interest ($M)248 · FY2025
- Operating Leases — Weighted-Average Discount Rate (%)3.5% · FY2025
Cite this data
StockData. (2026). Merck Operating Leases — Right-of-Use (ROU) Assets ($M), annual FY2019–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/lease-rou-assets
See every metric in the Merck KPI table. Data updated Oct 26, 2026.